Mutagenicity Testing of Medical Device Extracts: Standards, Methods, and Regulatory Requirements

Mutagenicity testing of medical device extracts is a core element of biological safety evaluation, determining whether substances that leach from device materials can induce gene mutations or chromosomal damage. This article provides a comprehensive technical overview of extract-based genotoxicity testing under ISO 10993-3 and ISO 10993-12, covering sample preparation, the Ames test and supplementary mammalian cell assays, evaluation criteria, and typical regulatory applications. It is intended as a practical reference for manufacturers, regulatory affairs professionals, and quality engineers planning compliant biological evaluation programs.

Technical Overview

Mutagenicity testing of medical device extracts is performed to determine whether chemical substances leaching from device materials under simulated clinical extraction conditions can induce genetic damage, including gene mutations, structural chromosome aberrations, and numerical chromosome changes. Because patients may be exposed to such leachables through mucosal membranes, breached or compromised skin, or direct blood contact, genotoxicity evaluation is an essential component of the biological safety assessment framework established in ISO 10993-1 and specified in detail in ISO 10993-3.

The evaluation follows a tiered, weight-of-evidence strategy. The bacterial reverse mutation test (Ames test) serves as the primary screening assay for point mutagenicity, typically complemented, where appropriate, by in vitro mammalian cell assays such as the chromosome aberration test, the in vitro micronucleus test, or the mouse lymphoma TK mutation assay. In vivo genotoxicity testing is conducted only when in vitro results are positive or when specific regulatory expectations apply. The test battery is structured so that different genetic endpoints—base-pair substitution, frameshift mutation, chromosome breakage, and chromosome loss—are covered by complementary assays.

Sample preparation is governed by ISO 10993-12 (and the equivalent Chinese national standard GB/T 16886.12), which defines extraction vehicles, extraction ratios, temperatures, and durations. Test performance aligns with internationally recognized OECD Test Guidelines, including TG 471 (bacterial reverse mutation test), TG 473 (mammalian chromosome aberration test), TG 487 (in vitro mammalian cell micronucleus test), and TG 490 (mouse lymphoma assay). Studies intended for regulatory submission are normally carried out in GLP-compliant, accredited third-party laboratories.

Testing Samples

Sample Types

Test samples should represent the final product in its sterilized, clinically used condition wherever possible. Common sample categories include:

• Polymeric components such as catheters, tubing sets, syringe barrels, infusion sets, and housings
• Metallic and alloy materials used in orthopedic implants, stents, needles, and surgical instruments
• Ceramic and composite materials used in dental and orthopedic applications
• Coatings, adhesives, surface treatments, printing inks, and labeling inks in direct material contact
• Textiles, films, wound dressings, hydrogels, and absorbent materials
• Processing aids, sterilization agent residues, and packaging materials in contact with the device

Sample Preparation Requirements

Samples are cut, cleaned, and sterilized using methods consistent with routine production, and particulate matter is removed before extraction. Extraction is performed under aseptic conditions using standardized ratios defined in ISO 10993-12, typically 6 cm²/mL for thin materials (thickness ≤ 0.5 mm), 3 cm²/mL for thicker materials, and 0.1–0.2 g/mL for materials characterized by mass, such as porous or absorbent products. For genotoxicity testing, ISO 10993-3 recommends exaggerated extraction ratios and conditions relative to routine toxicity testing in order to maximize the concentration of leachable substances and improve detection sensitivity.

Extraction Conditions and Vehicles

Because leachables may span a wide polarity range, extraction is generally performed with both a polar and a non-polar vehicle, and an additional solvent may be selected when justified by the chemical nature of the materials:

• Polar vehicles: physiological saline (0.9% sodium chloride) or serum-free culture medium
• Non-polar vehicles: vegetable oils such as sesame oil or cottonseed oil
• Additional genotoxicity vehicles: dimethyl sulfoxide (DMSO), ethanol/water mixtures, or other solvents demonstrated to be compatible with the test systems
• Standard condition: 37 ± 1 °C for 72 ± 2 hours; alternative accelerated conditions include 50 °C for 72 hours, 70 °C for 24 hours, or 121 °C for 1 hour for heat-stable materials

Testing Items

Bacterial Reverse Mutation Test (Ames Test)

The Ames test is the first-line assay for extract mutagenicity. Histidine-auxotrophic strains of Salmonella typhimurium (typically TA1535, TA1537 or TA97a, TA98, TA100, and TA102) and, where appropriate, tryptophan-auxotrophic Escherichia coli strains (WP2 uvrA or WP2 pKM101) are exposed to serial dilutions of the device extract. Revertant colony counts are compared with vehicle controls to detect base-pair substitution and frameshift mutagenicity.

In Vitro Mammalian Chromosome Aberration Test

This assay detects structural chromosome damage in mammalian cells, typically human peripheral blood lymphocytes or Chinese hamster cell lines such as CHO or CHL. Cells are treated with the extract in the absence and presence of metabolic activation, and metaphase spreads are analyzed for chromatid and chromosome breaks, exchanges, and other aberrations.

In Vitro Micronucleus Test

The in vitro micronucleus assay identifies both clastogenic agents (chromosome-breaking substances) and aneugenic agents (substances causing whole-chromosome loss). Micronucleus frequency in treated cells is scored by microscopy or automated image analysis, together with cytotoxicity markers such as replication index or cytokinesis-block proliferation index.

Mouse Lymphoma TK Mutation Assay

The mouse lymphoma assay using the L5178Y tk⁺/tk⁻ cell line detects a broad spectrum of genetic damage, including gene mutation, deletion, and chromosomal recombination, at the thymidine kinase locus. Colony sizing distinguishes large-colony (gene mutation) from small-colony (chromosomal-level damage) events.

In Vivo Genotoxicity Follow-up Testing

When in vitro results are positive or when a weight-of-evidence assessment requires additional data, in vivo assays such as the rodent bone marrow micronucleus test or the comet assay may be performed to assess genotoxicity under whole-animal exposure and metabolism conditions.

Testing Methods

Test Performance

The Ames test is commonly conducted using both the plate incorporation method and the pre-incubation method, particularly for extracts that may contain volatile or poorly diffusing substances. All assays are performed in the absence and presence of an exogenous metabolic activation system (S9 mix), conventionally prepared from the livers of rats induced with phenobarbital and β-naphthoflavone or with Aroclor 1254. At least five analyzable concentration levels are evaluated per extract, with the highest concentration limited by cytotoxicity, precipitation, or the maximum achievable extract concentration.

Control Design

• Negative and vehicle controls to define baseline mutation frequencies
• Strain-specific positive controls without metabolic activation, such as sodium azide, 4-nitroquinoline N-oxide, mitomycin C, ICR-191, or 9-aminoacridine
• Positive controls with metabolic activation, typically 2-aminoanthracene or benzo[a]pyrene
• Cytotoxicity controls and sterility controls for each extraction vehicle

Evaluation Criteria

An extract is considered mutagenic when a reproducible, biologically relevant, dose-related increase in revertant counts or aberration/micronucleus frequency is observed, conventionally reaching at least twice the concurrent vehicle control value for revertant counts in the Ames test, provided all assay validity criteria are met. A result is considered negative when no such increase occurs up to cytotoxic or maximum feasible concentrations. Borderline or discordant findings are resolved through repeat testing or supplemental assays.

Quality Assurance and Compliance

Testing is performed under Good Laboratory Practice (GLP) principles with characterized, periodically checked tester strains and cell lines, documented positive control performance within historical control limits, and independent quality assurance review. Laboratories supporting regulatory submissions typically hold ISO/IEC 17025 accreditation for the relevant biological test methods.

Applications

Extract mutagenicity testing supports biological safety documentation for regulatory submissions to authorities such as the China National Medical Products Administration (NMPA), the United States Food and Drug Administration (FDA), and European notified bodies under the EU Medical Device Regulation. Key applications include:

• Registration dossiers for Class II and Class III devices requiring genotoxicity data under ISO 10993-1 biological evaluation plans
• Biological evaluation reports supporting ISO 14971 risk management files
• Verification after material substitutions, supplier changes, manufacturing process changes, or sterilization method changes, including evaluation of ethylene oxide and radiation-induced degradation products
• Supporting data for extractables and leachables (E&L) studies on infusion devices, drug-delivery combination products, and container closure systems
• Safety assessment of chronic-contact and permanent devices such as implants, pacemaker leads, intraocular lenses, hemodialyzers, and dental restorative materials

FAQ

Do all medical devices require extract mutagenicity testing?

No. The requirement is determined by the risk-based categorization in ISO 10993-1, which considers body contact type and contact duration. Genotoxicity testing is generally expected for devices with prolonged or permanent contact with tissue, bone, dentin, or blood, and for devices with mucosal or breached-skin contact exceeding 30 days. Surface devices contacting intact skin for short durations typically do not require genotoxicity testing.

Why are both polar and non-polar extraction vehicles required?

Device materials can release both water-soluble substances, such as ionic species and polar additives, and lipophilic substances, such as plasticizers, oligomers, and processing aids. Using a polar vehicle (saline or culture medium) and a non-polar vehicle (vegetable oil), sometimes supplemented by DMSO for genotoxicity work, ensures that leachables across the full polarity spectrum are captured and evaluated.

How is the highest test concentration selected?

For in vitro assays, the maximum concentration is normally the highest non-cytotoxic concentration achievable from the extract, taking into account vehicle compatibility, precipitation, and pH or osmolality effects. When the extract causes no cytotoxicity or precipitation, testing proceeds at the maximum practicable concentration of the neat extract or its concentrates, consistent with OECD guidance and ISO 10993-3 recommendations.

What happens if a positive result is obtained?

A positive in vitro finding does not automatically disqualify the device. The standard follow-up includes confirmatory repeat testing, analytical chemistry to identify the causative leachable, assessment of patient exposure relative to toxicological thresholds, and, where warranted, in vivo genotoxicity testing. A benefit-risk evaluation is then performed within the device risk management framework.

How much sample is needed and how long does testing take?

Typical sample requirements are on the order of 3–10 g of material or an equivalent surface area, divided between the extraction vehicles and any repeat or confirmatory phases. The Ames test alone is usually completed within four to six weeks; a full battery combining the Ames test with a chromosome aberration or micronucleus test generally requires six to ten weeks, excluding sample preparation and shipping time.